Business
Confirmation of change of Auditor
Confirmation of change of Auditor.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 2709S Oxford Biomedica PLC 22 June 2018 \n\n \n \n \n \n \n \nConfirmation of change of Auditor\nLondon, UK - 22 June 2018: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, today announces that it has appointed KPMG LLP as the auditor to the Company as approved by the shareholders at the Company's Annual General Meeting held on 29 May 2018.\n \nPricewaterhouseCoopers LLP has resigned as the Company's auditor and has confirmed to the Company that, in accordance with Section 519 of the Companies Act 2006, there are no circumstances in connection with its resignation which it considers need to be brought to the attention of the Company's members or creditors.\n \n- Ends -\n \n \n\n\n\nFor further information, please contact:\n \n\n\n \n\n\n\nOxford BioMedica plc: Tel: +44 (0)1865 783 000\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\n \nFinancial PR Enquiries: Tel: +44 (0)20 3709 5700\nConsilium Strategic Communications\nMary-Jane Elliott / Matthew Neal /\nOliver Manser / Laura Thornton\n \n \nNotes for editors\n \n \nAbout Oxford BioMedica\nOxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Gro...